Uxin shares drop 45% as predicted by InvestingPro’s Fair Value model
Waters also highlighted its ongoing integration planning for the BD Biosciences acquisition, expected to close in Q1 2026. The company reported that integration planning is "well underway and progressing rapidly," with synergy delivery action plans established across multiple business and functional workstreams.
Looking further ahead, Waters outlined plans for 2026 focused on expanding its Empower software platform, which currently has 420,000 users. The company intends to extend compliant informatics to bioanalytics and drive transition from on-premises installations to a subscription model, leveraging AI/ML capabilities to enhance utilization and minimize compliance risks.
Despite the positive outlook, investors should consider potential risks including supply chain disruptions, market saturation in key segments, macroeconomic pressures, regulatory changes, and integration challenges associated with the upcoming BD Biosciences acquisition.
With strong Q3 results and raised guidance, Waters continues to demonstrate the effectiveness of its innovation-driven growth strategy, particularly in high-growth pharmaceutical applications and emerging markets.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.